Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants

被引：18

作者：

Sivolella, Stefano ^{[1
]}

De Biagi, Marleen ^{[1
,2
]}

Brunello, Giulia ^{[1
]}

Berengo, Mario ^{[1
]}

Pengo, Vittorio ^{[3
]}

机构：

[1] Univ Padua, Dept Neurosci, Inst Clin Dent, Via Venezia 90, I-35129 Padua, Italy

[2] Univ Padua, Azienda Osped, Inst Clin Dent, Via Venezia 90, I-35129 Padua, Italy

[3] Padova Univ Hosp, Dept Cardiac Thorac & Vasc Sci, Via Giustiniani 2, I-35128 Padua, Italy

来源：

ODONTOLOGY | 2015年 / 103卷 / 03期

关键词：

Dabigatran; Rivaroxaban; Apixaban; Oral anticoagulants; Oral surgery; DIRECT THROMBIN INHIBITOR; DABIGATRAN ETEXILATE; MANAGEMENT; RECOMMENDATIONS; RIVAROXABAN; ANTIDOTE; REVERSAL; WARFARIN; CARE;

D O I：

10.1007/s10266-015-0195-4

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

The development of new orally administered anticoagulants, such as dabigatran, rivaroxaban, and apixaban, in the past few years has focused on avoiding some of the drawbacks associated with warfarin. This work aims to illustrate the main features of the most commonly used new oral anticoagulants, reviewing the current literature on the management of patients taking these drugs and needing oral and implant surgery, and discussing the currently proposed related guidelines.

引用

页码：258 / 263

页数：6

共 37 条

[1] Oral and parenteral anticoagulants: New kids on the block [J].